Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kawamori, R. | - |
dc.contributor.author | Iwamoto, Y. | - |
dc.contributor.author | Kadowaki, T. | - |
dc.contributor.author | Iwasaki, M. | - |
dc.contributor.author | Kim, S. -W. | - |
dc.contributor.author | Woo, J. -T. | - |
dc.contributor.author | Baik, S. -H. | - |
dc.contributor.author | Yoon, K. -H. | - |
dc.date.accessioned | 2021-09-08T13:49:34Z | - |
dc.date.available | 2021-09-08T13:49:34Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2009-09 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/119377 | - |
dc.description.abstract | Aim To evaluate the safety and efficacy of insulin glulisine (glulisine) with and without oral antidiabetic drugs (OAD; sulphonylurea or sulphonylurea + biguanide) relative to that of OAD alone in Japanese and Korean patients with inadequately controlled type 2 diabetes mellitus (T2DM). Methods In an open, randomized, parallel-group, comparative, controlled trial, 387 patients were randomized and treated with glulisine + OAD (n = 130), glulisine monotherapy (n = 127) or OAD only (n = 130) for 16 weeks. Glulisine was self-injected subcutaneously three times daily (0-15 minutes before meals) at a starting dose of >= 0.2 U/kg/day. Patients titrated the glulisine dose to achieve a 2-h postprandial plasma glucose (2h-PPG) level of 7.1-9.5 mmol/l (128-172 mg/dl) by administering at least one additional unit at each appropriate meal time if the 2h-PPG level was > 9.5 and < 11.1 mmol/l (> 172 and < 200 mg/dl) and by administering at least two additional units if the 2h-PPG level was >= 11.1 mmol/l (>= 200 mg/dl). Therapy with OAD was continued at the stable baseline regimen. The primary efficacy endpoint was change in haemoglobin A(1c) (HbA(1c)) from baseline to endpoint in the intention-to-treat population. Results At baseline, therapy with OAD was a sulphonylurea only and a sulphonylurea + a biguanide in approximately 24 and 76% of patients respectively. Both glulisine groups had larger reductions in adjusted mean HbA(1c) than the OAD-only group (glulisine + OAD, -2.07%; glulisine monotherapy, -1.25%; OAD only, -0.61%). Superiority of glulisine + OAD and glulisine monotherapy vs. OAD only was shown by differences in adjusted mean HbA(1c) change from baseline values of -1.46% (p < 0.0001) and -0.64% (p < 0.0001) respectively. Both glulisine groups had better 2h-PPG control than the OAD-only group. Mean daily glulisine doses increased from baseline to endpoint (glulisine + OAD, 13.3-22.5 U; glulisine monotherapy, 14.2-38.0 U). The rate of all symptomatic hypoglycaemia events per patient-year in the entire treatment phase was 11.9 in the glulisine + OAD group, 8.8 in the glulisine monotherapy group and 1.7 in the OAD-only group. There was only one event of severe hypoglycaemia, which occurred in the glulisine + OAD group. Efficacy and safety were similar in Japanese and Korean subpopulations. Conclusions Both glulisine + OAD and glulisine monotherapy were well tolerated and effective for Japanese and Korean patients with T2DM mellitus inadequately controlled by OAD therapy alone. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | REGULAR HUMAN INSULIN | - |
dc.subject | GLYCEMIC CONTROL | - |
dc.subject | GLUCOSE | - |
dc.subject | PHARMACODYNAMICS | - |
dc.subject | PHARMACOKINETICS | - |
dc.subject | HYPERGLYCEMIA | - |
dc.subject | GLARGINE | - |
dc.subject | BASAL | - |
dc.title | Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Baik, S. -H. | - |
dc.identifier.doi | 10.1111/j.1463-1326.2009.01088.x | - |
dc.identifier.scopusid | 2-s2.0-69249215409 | - |
dc.identifier.wosid | 000269183800009 | - |
dc.identifier.bibliographicCitation | DIABETES OBESITY & METABOLISM, v.11, no.9, pp.900 - 909 | - |
dc.relation.isPartOf | DIABETES OBESITY & METABOLISM | - |
dc.citation.title | DIABETES OBESITY & METABOLISM | - |
dc.citation.volume | 11 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 900 | - |
dc.citation.endPage | 909 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | REGULAR HUMAN INSULIN | - |
dc.subject.keywordPlus | GLYCEMIC CONTROL | - |
dc.subject.keywordPlus | GLUCOSE | - |
dc.subject.keywordPlus | PHARMACODYNAMICS | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | HYPERGLYCEMIA | - |
dc.subject.keywordPlus | GLARGINE | - |
dc.subject.keywordPlus | BASAL | - |
dc.subject.keywordAuthor | glycated haemoglobin A(1c) | - |
dc.subject.keywordAuthor | insulin glulisine | - |
dc.subject.keywordAuthor | type 2 diabetes | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.